Molecular Templates Inc (MTEM) Return on Investment ROI from the second quarter of 2024 to second quarter of 2023 and for the year 2024, average high and low, overall ranking from Jun 30 2024 to Jun 30 2023 - CSIMarket
CSIMarket
 


Molecular Templates Inc   (NASDAQ: MTEM)


Molecular Templates Inc's ROI from its second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Molecular Templates Inc's ROI in the second quarter of 2024?
Molecular Templates Inc recorded a cumulative net loss of $-48 million during 12 months ending in the second quarter of 2024, resulting in a negative return on investment (ROI) of -247.98%.

Within the Healthcare sector 813 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2024 from 3172 to 4334.

Definition and Formula of Return on Investment



Return On Investment (Jun 30 2024)
II. Quarter
(Mar 31 2024)
I. Quarter
(Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
Y / Y Investment Change TTM -39.77 % -67.33 % -69.17 % -75.13 % -73.6 %
Y / Y Net Income Change TTM - - - -46.64 % 91.09 %
Investment (TTM) in Millions 19 19 18 23 9
Return On Investment (TTM) -247.98 % -302.58 % -190.15 % 108.71 % 143.82 %
MTEM's Overall Ranking # 4334 # 3172 # 343 # 27 # 0
Seq. Investment Change TTM 15.42 % -21.39 % -10.56 % -25.78 % -37.39 %
Seq. Net Income Change TTM - - - -43.9 % -43.06 %
Net Income (TTM) in Millions -48 -51 -41 26 47




Return On Investment MTEM's Ranking
Within: No.
Industry # 382
Sector # 814
Overall # 4334

Return On Investment Statistics
High Average Low
212.57 %
32.14 %
-167.43 %
(Sep 30 2023)   (Jun 30 2024)







Financial Statements
Molecular Templates Inc's II. Quarter Investments $ 19 Millions MTEM's Balance sheet
Molecular Templates Inc's II. Quarter Income $ -8 Millions Quarterly MTEM's Income Statement
MTEM's Income by Division See MTEM's Income by Division


MTEM Annual Return On Investment (Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
(Dec 31 2019)
2019
Total Investments in Millions 18 28 136 102 127
Y / Y Investment Growth -36.03 % -79.26 % 33.04 % -19.25 % 17.71 %
Net Income in Millions 8 93 83 105 69
Y / Y Net Income Growth -91.24 % 11.7 % -20.88 % 51.13 % 129.21 %
Annual Return On Investment 44.98 % 328.38 % 60.98 % 102.53 % 54.78 %


Annual Roi Comment
In the fiscal year 2023 ROI decreased relative to the previous year to 44.98 %, due to deterioration of net income.

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
MTEM's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for MTEM's Competitors
Subscribers only: Roi for Molecular Templates Inc's Suppliers
Subscribers only: Return On Investment for MTEM's Customers

Other Ratios
MTEM's Roa MTEM's Inventory Turnover Ratio MTEM's Growth Rates MTEM's Dividend Statistics
MTEM's Profitability Ratios MTEM's Asset Turnover Ratio MTEM's Dividend Growth
MTEM's Roe MTEM's Valuation Ratios MTEM's Financial Strength Ratios MTEM's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2024, within Healthcare Sector ROI


Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.